Skip to content
Evigrade
CriticalClass III antiarrhythmic, selective IKr blocker×First-generation antihistamine with anxiolytic activity

Updated · Methodology

Mechanism

Hydroxyzine has been associated with QT prolongation. Post-marketing reports describe QT prolongation and torsade de pointes, mostly in people with other risk factors, electrolyte disturbances and concomitant medicines (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is a class III antiarrhythmic. It blocks the rapid component of the delayed rectifier potassium current (IKr), and QT prolongation depends directly on its plasma concentration. Dofetilide can cause serious ventricular arrhythmias, mainly torsade de pointes (dofetilide label, US Food and Drug Administration, FDA). The Spanish hydroxyzine SmPC names class III antiarrhythmics among the drugs that raise the risk of arrhythmia when taken with hydroxyzine (AEMPS). The documents describe no pharmacokinetic interaction for this pair. Alcohol dehydrogenase and CYP3A4/5 metabolise hydroxyzine (AEMPS), and dofetilide does not inhibit cytochrome P450 enzymes (FDA).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The Medication Guide of the US dofetilide label lists the warning signs of a dangerous arrhythmia: feeling faint, dizziness and a fast heartbeat. It warns that torsade de pointes can lead to death. In people with supraventricular arrhythmias who took dofetilide, torsade de pointes occurred in 0.8%, mostly within the first three days of treatment (dofetilide label, US Food and Drug Administration, FDA). The adverse reactions of hydroxyzine include QT prolongation and ventricular arrhythmias, including torsade de pointes, with unknown frequency. Tachycardia is rare (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs known to prolong the QT interval or cause torsade de pointes and names class III antiarrhythmics among them (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is a class III antiarrhythmic that prolongs QT and can cause torsade de pointes (dofetilide label, US Food and Drug Administration, FDA). The US dofetilide label does not recommend dofetilide with other QT-prolonging drugs (FDA). The US hydroxyzine label advises caution with class III antiarrhythmics and other QT-prolonging drugs (hydroxyzine FDA label). Dofetilide is not in the Spanish medicines register CIMA. Hydroxyzine is also contraindicated in known QT prolongation, pre-existing cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (AEMPS). If hydroxyzine and dofetilide have nevertheless been taken together and signs of arrhythmia appear, stop hydroxyzine (AEMPS). If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug (FDA). No document states how long to wait after stopping hydroxyzine before starting dofetilide. The half-life of hydroxyzine in adults is about 14 hours (AEMPS). Start or restart dofetilide only in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and perform cardiac resuscitation for at least three days. Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) is above 440 ms (500 ms with ventricular conduction abnormalities). Keep potassium in the normal range before and during treatment (FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dofetilide

Other interactions with Hydroxyzine